Massey Physicians named Richmond Magazine’s Top Docs 2016
VCU Massey Cancer Center physicians again were recognized in Richmond Magazine’s annual list of “Top Docs.” Featured in the magazine’s April 2016 issue, the list includes 31 doctors from varied specialties who provide oncology-related care to Massey’s patients, including 10 who care for pediatric patients at the Children’s Hospital of Richmond at VCU. The selections were the result of a survey that asked Richmond-area physicians who they would recommend in a range of specialties.
Massey opens clinical trial testing a combination of Viagra and chemo to treat advanced solid tumors
VCU Massey Cancer Center has developed and opened a Phase 1 clinical trial to study the effects of Viagra in combination with chemotherapy to treat patients with progressive, advanced solid tumors. The trial is a result of previous research conducted at Massey by a group of researchers including physician-scientist Andrew Poklepovic, M.D., who is the leading the trial as its principal investigator. Their research demonstrated that regorafenib (trade name Stivarga), a type of chemotherapy, interacts with Viagra (generic name sildenafil), a medication originally developed for erectile dysfunction, to kill tumor cells significantly better than regorafenib alone.
Massey researchers identify patients at risk for stem cell transplant complications
Researchers at VCU Massey Cancer Center’s Bone Marrow Transplant Program have recently published findings from a phase 2 clinical trial that demonstrate lymphocyte recovery in related and unrelated stem cell transplant recipients generally falls into three patterns that are significantly associated with survival. This first-of-its-kind research continues the efforts of principal investigator Amir Toor, M.D., to understand the immune system as a dynamical system that can be modeled to improve stem cell transplantation.
Massey becomes the only medical provider in Richmond to offer Interleukin-2 therapy
VCU Massey Cancer Center is now offering FDA-approved Interleukin-2 (IL-2) therapy for metastatic melanoma and metastatic renal cell carcinoma, making Massey the only medical provider in the Richmond area to offer this service. IL-2 treatment is a type of immunotherapy that stimulates the body’s immune system to recognize and kill tumor cells.
National clinical trials offered at Massey utilize precision medicine aimed at improving treatment of early-stage lung cancer
VCU Massey Cancer Center is currently offering clinical trials for patients with early-stage lung cancer that utilize cutting-edge precision medicine techniques with the aim of improving treatment. This group of three integrated national clinical trials known as ALCHEMIST – Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trials – use next-generation sequencing to identify patients with early-stage lung cancer whose tumors harbor specific and uncommon changes in two particular genes, epidermal growth factor receptor (EGFR) and anaplastic lymphoma receptor tyrosine kinase (ALK), thought to drive cancer growth.